SCM
SABSW icon

Shaolin Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Shaolin Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-249,143
Closed -$11.8K – 298
2024
Q2 		$11.8K Sell
249,143
-43,822
-15% -$1.62K ﹤0.01% 276
2024
Q1 		$11.4K Sell
292,965
-78,676
-21% -$2.12K ﹤0.01% 281
2023
Q4 		$11.2K Sell
371,641
-94,076
-20% -$5.66K ﹤0.01% 335
2023
Q3 		$33K Buy
+465,717
New +$42.8K ﹤0.01% 347
2023
Q2 		– Sell
-498,109
Closed -$52.1K – 681
2023
Q1 		$18K Hold
498,109
– – ﹤0.01% 571
2022
Q4 		$23K Sell
498,109
-164,590
-25% -$10K ﹤0.01% 565
2022
Q3 		$41K Sell
662,699
-161,300
-20% -$19.2K ﹤0.01% 600
2022
Q2 		$156K Sell
823,999
-1,000
-0.1% -$228 ﹤0.01% 552
2022
Q1 		$397K Sell
824,999
-16,796
-2% -$14.2K 0.01% 511
2021
Q4 		$1.51M Buy
841,795
+457,528
+119% +$840K 0.04% 422
2021
Q3 		$354K Buy
384,267
+79,182
+26% +$56.6K 0.01% 404
2021
Q2 		$281K Buy
305,085
+65,858
+28% +$47.8K 0.01% 435
2021
Q1 		$144K Buy
+239,227
New +$249K 0.01% 460

Other funds holding SABSW

HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Shaolin Capital Management's SABSW Position: Q3 2024 in Review

Shaolin Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q3 2024, closing a stake of 249,143 shares — an estimated $11.8K sold.

Shaolin Capital Management first reported a position in SABSW in Q1 2021 and held it in 13 quarters. The position peaked at $1.51M in Q4 2021. 9 funds tracked by Wall St. Rank hold SABSW as of Q3 2024.

  • Shaolin Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q3 2024 after selling out during the quarter.
  • Shaolin Capital Management sold 249,143 SAB Biotherapeutics Warrant shares in Q3 2024, an estimated $11.8K.
  • Shaolin Capital Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 13 quarters.
  • Shaolin Capital Management's SAB Biotherapeutics Warrant position peaked at $1.51M in Q4 2021.
  • 9 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q3 2024.

Based on Shaolin Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.